Improving CAR T Cell Therapy for B Cell Malignancies
The Role of CD3z ITAM (Immunoreceptor Tyrosine-Based Activation Motif) diversity in CAR T cell Force and Function
This work looks at how to make CAR T cells work better and last longer for people with B cell cancers, aiming to reduce side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11131019 on NIH RePORTER |
What this research studies
CAR T cell therapy uses your own immune cells, called T cells, engineered to recognize and fight cancer. While powerful, current CAR T cell treatments can have serious side effects and sometimes don't last long enough. This project explores how to fine-tune the internal signals within CAR T cells to make them more effective and persistent against cancer. By understanding how different parts of the CAR T cell's signaling machinery work, we hope to design safer and more potent therapies. Our goal is to overcome current limitations and improve outcomes for patients with B cell malignancies.
Who could benefit from this research
Good fit: This foundational work is relevant for patients with B cell malignancies who may be candidates for CAR T cell therapy in the future.
Not a fit: Patients with conditions other than B cell malignancies or those not suitable for CAR T cell therapy may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to CAR T cell therapies that are more effective, last longer, and have fewer severe side effects for patients with B cell cancers.
How similar studies have performed: While CAR T cell therapy has shown success, this particular approach to optimizing internal signaling pathways is a novel area of exploration.
Where this research is happening
Salt Lake City, United States
- Utah State Higher Education System--University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Bettini, Matthew — Utah State Higher Education System--University of Utah
- Study coordinator: Bettini, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.